InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,214.08
(
0.51%
)
US TECH 100
17,658.00
(
0.32%
)
Dow Jones
39,387.76
(
0.85%
)
Brent Oil
84.29
(
0.40%
)
Bitcoin
62,927.46
(
-0.19%
)
Post# of 251777
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

mcbio

Send PM Follow Ignore
Followers 69
Posts 6152
Boards Moderated 0
Alias Born 11/26/2008

mcbio

Re: biocqr post# 220718

Tuesday, 08/06/2019 10:46:43 PM

Tuesday, August 06, 2019 10:46:43 PM

Post# of 251777
XENE - 2Q19 CC note

XENE > FDA gives OK for XEN496 in single pivotal Phase 3 trial for KCNQ2 epilepsy...

Based on the CC today, the CEO mentioned that he expects XENE will need to show about a 30-40% delta for XEN496 response vs. placebo in the P3 for KCNQ2-EE.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up